Suppressing activity of the AKT/mTOR pathway with some of the factors effectively inhibits the tumor tissue activity (132, 133), but endometrial cancer therapies engaging only a single inhibiting factor are insufficiently effective as monotherapy (134); thus, using some factors enhancing the suppressing mTOR inhibitors effect significantly intensifies reducing endometrial cancer cell viability, colony formation ability, and induced apoptosis (135). The gene discussed is MTOR; the disease is neoplasm.